CD16 (FCGR3A) Human Recombinant Protein

CAT#: TP721246

Human CD16a Protein (C-His-Avi, 176V)

Product Images

Human CD16a protein (C-His-Avi) is coated at 8ug/mL (100u/well). Human IgG1 can bind human CD16a protein in the dose dependant manner. The EC50 is about 100-400 ng/mL.

• 

  Human CD16a protein (C-His-Avi) on SDS-PAGE under reducing condition P(+) and non-reducing condition P(-) . The purity of this protein appears to be greater than 95% based on Coomassie-blue staining.

Specifications

Product Data

• Species: Human
• Expression Host: HEK293
• Expression cDNA Clone or AA Sequence:
  Protein Sequence

  Gly17-Gln208
• Tag: C-His-Avi
• Predicted MW: The protein has the predicted molecular weight of 25.5 kDa and migrates at approximately 40-50 kDa on SDS-PAGE with DTT-reduced condition.
• Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is bottled at lot specific concentration.
• Purity: >90%
• Buffer: 1xPBS buffer, pH7.4
• Bioactivity: Positive
  
  The definition of the active protein (purified and biotinylated) is defined as the protein that can bind to its biological receptor/ligand. For conjugated protein, it is defined with its function to bind to the ScFv of the active CAR-transfected cells in flow cytometry test.
• Preparation: Affinity Ni-NTA
• Applications: ELISA
• Storage: An unopened vial can be stored at 4°C for 2 weeks or at -20°C and below for six months. This stock solution should be aliquoted and stored at ≤ -70°C to minimize the freeze/thaw cycles.
• Stability: 6 Months

Reference Data

• RefSeq: NP_001121068
• Locus ID: 2214
• UniProt ID: P08637
• Summary: CD16a (FCGR3A) and its homolog CD16b are receptors for the Fc portion of human IgG. In contrast to CD64, which is a high affinity Fc binding protein, both CD16a and CD16b can bind Fc portion of human IgG with relative low affinity. Human CD16a is expressed mainly on natural killer cells, macrophages, T cells, and monocytes. While human CD16b is expressed on Neutrophils and eosinophils. In human cells, a single nucleotide polymorphism (T230A) creates a high binding (176V) and a low binding (176F) variant. Clinically, mutations in CD16a have been linked to vulnerability to viral infections, alloimmune neonatal neutropenia, and systemic lupus erythematosus.